Elder Pharma gets Japanese approval for API facility

today said it has received approval for its manufacturing facility in Maharashtra from the Japan health ministry.

The company has received accreditation from Ministry of Health-Japan for its active pharmaceutical ingredients (API) plant at Patalganga, Maharashtra, opening up the fast growing Japanese markets for the company's products, Elder Pharma said in a statement to the Bombay Stock Exchange (BSE).

"Elder is positioning itself to be an API and advanced intermediate supplier to Japanese market. This accreditation for the API plant is a step towards strengthening Elder's position as a supplier of APIs and intermediates in the Japanese market," Elder Pharma Director Alok Saxena said.

The Mumbai-based company has also developed products for the Japanese market.

"The company has developed two products going off patent in the Japanese market in 2014. One of the products is from CNS category and the second one is from GI segment," Saxena said.

The company has already filed a patent application for one of the advanced intermediates for the Japanese market and is in talks with Japanese generic for supply contracts, it said.

Japanese pharmaceutical market, which is valued at $69.4 billion in 2009, is the second largest pharma market in the world.

Shares of Elder Pharma were today trading at Rs 372.10 on in the late afternoon trade, up by 0.57 per cent from its previous close.

image
Business Standard
177 22
Business Standard

Elder Pharma gets Japanese approval for API facility

Press Trust of India  |  New Delhi 



today said it has received approval for its manufacturing facility in Maharashtra from the Japan health ministry.

The company has received accreditation from Ministry of Health-Japan for its active pharmaceutical ingredients (API) plant at Patalganga, Maharashtra, opening up the fast growing Japanese markets for the company's products, Elder Pharma said in a statement to the Bombay Stock Exchange (BSE).

"Elder is positioning itself to be an API and advanced intermediate supplier to Japanese market. This accreditation for the API plant is a step towards strengthening Elder's position as a supplier of APIs and intermediates in the Japanese market," Elder Pharma Director Alok Saxena said.

The Mumbai-based company has also developed products for the Japanese market.

"The company has developed two products going off patent in the Japanese market in 2014. One of the products is from CNS category and the second one is from GI segment," Saxena said.

The company has already filed a patent application for one of the advanced intermediates for the Japanese market and is in talks with Japanese generic for supply contracts, it said.

Japanese pharmaceutical market, which is valued at $69.4 billion in 2009, is the second largest pharma market in the world.

Shares of Elder Pharma were today trading at Rs 372.10 on in the late afternoon trade, up by 0.57 per cent from its previous close.

RECOMMENDED FOR YOU

Elder Pharma gets Japanese approval for API facility

Elder Pharmaceuticals today said it has received approval for its manufacturing facility in Maharashtra from the Japan health ministry.

today said it has received approval for its manufacturing facility in Maharashtra from the Japan health ministry.

The company has received accreditation from Ministry of Health-Japan for its active pharmaceutical ingredients (API) plant at Patalganga, Maharashtra, opening up the fast growing Japanese markets for the company's products, Elder Pharma said in a statement to the Bombay Stock Exchange (BSE).

"Elder is positioning itself to be an API and advanced intermediate supplier to Japanese market. This accreditation for the API plant is a step towards strengthening Elder's position as a supplier of APIs and intermediates in the Japanese market," Elder Pharma Director Alok Saxena said.

The Mumbai-based company has also developed products for the Japanese market.

"The company has developed two products going off patent in the Japanese market in 2014. One of the products is from CNS category and the second one is from GI segment," Saxena said.

The company has already filed a patent application for one of the advanced intermediates for the Japanese market and is in talks with Japanese generic for supply contracts, it said.

Japanese pharmaceutical market, which is valued at $69.4 billion in 2009, is the second largest pharma market in the world.

Shares of Elder Pharma were today trading at Rs 372.10 on in the late afternoon trade, up by 0.57 per cent from its previous close.

image
Business Standard
177 22
Widgets Magazine

More News

  • Kova kozhukattai Now, Rajan on your plate
  • Uber says limited licences curb growth in Kolkata
Widgets Magazine
Widgets Magazine

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard